BioWorld

Jan. 20, 2009

Peptimmune, Novartis Sign $500M Deal for MS Drug

Peptimmune Inc., a privately held U.S. biotechnology company, has granted Novartis AG an exclusive option to license its drug candidate for multiple sclerosis, PI-2301. (BioWorld Today) Read More

Drop in Manufacturing Demand Prompts Cuts to XOMA's Staff

Will Health Care Reform Save Biotech, Economy

NewCo News: Carolus Therapeutics Wants to be King of Cytokine Targeting

Holiday Notice

Corrections & Clarifications

FDA Issues Final Guidance on Rules for GE Animals

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 24, 2025.

Moderna expands mRNA tech to latent viruses, cancer, rare disease

BioWorld

Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

Otsuka licenses Harbour’s bispecific T-cell engager for $670M

BioWorld

Harbour Biomed is out-licensing its B-cell maturation antigen and CD3 bispecific T-cell engager HBM-7020 for autoimmune diseases to Otsuka Pharmaceutical Co. Ltd....

Revmed goes global with $2B in capital for RAS(ON) inhibitors

BioWorld

Taking an unconventional path to market for its targeted therapies for RAS-addicted cancers, Revolution Medicines Inc. secured access to $2 billion in capital to...